Author: Dr. Vikram Chauhan

Upadacitinib: The JAK1 Switch Turning Down Inflammation In Rheumatoid Arthritis

Upadacitinib: The JAK1 Switch Turning Down Inflammation In Rheumatoid Arthritis—RA Care Pack As An Ayurvedic Alternative

Abstract

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterised by persistent synovial inflammation, pain, swelling, stiffness, progressive joint damage, and functional impairment. Although conventional and biologic disease-modifying antirheumatic drugs (DMARDs) have transformed RA management, some patients continue to experience inadequate disease control or intolerance to existing therapies. Upadacitinib is an orally administered, selective Janus kinase 1 (JAK1) inhibitor that targets intracellular signalling pathways involved in the production and activity of multiple inflammatory cytokines. By reducing JAK1-dependent signalling, it can suppress inflammatory activity and improve clinical manifestations of RA. Clinical trials have demonstrated improvements in disease activity, physical function, pain, morning stiffness, and remission rates, including in patients with inadequate responses to conventional synthetic or biologic DMARDs. Long-term studies have continued to demonstrate sustained efficacy, although careful monitoring for infections, herpes zoster, laboratory abnormalities, thrombosis, malignancy, and cardiovascular events remains essential. This article reviews the mechanism, therapeutic role, clinical evidence, safety considerations, and potential Ayurvedic interpretation of upadacitinib in rheumatoid arthritis.

Upadacitinib

Introduction

Rheumatoid arthritis is an immune-mediated inflammatory disorder in which dysregulated immune responses primarily affect the synovial joints. Persistent inflammation can cause synovial hypertrophy, cartilage destruction, bone erosion, deformity, and loss of physical function. The disease may also involve organs beyond the musculoskeletal system, making RA a systemic condition rather than simply a disorder of the joints. Modern treatment aims to achieve remission or sustained low disease activity through early and appropriately targeted DMARD therapy. Methotrexate remains a major component of initial treatment, while biologic DMARDs and targeted synthetic DMARDs are used when disease activity remains inadequately controlled. Upadacitinib has emerged as an important targeted synthetic DMARD. Unlike biologic medicines that generally act outside the cell by binding specific inflammatory mediators or their receptors, upadacitinib works inside immune cells by inhibiting JAK1-mediated signalling. This intracellular mechanism allows it to influence several cytokine pathways simultaneously.

Understanding the JAK-STAT Pathway

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is an important communication system used by numerous cytokine receptors. When a cytokine binds to its receptor, associated JAK proteins become activated and phosphorylate STAT proteins. STATs then enter the nucleus and regulate gene expression involved in immune activation, inflammation, cell survival, and differentiation. JAK1 participates in signalling from several cytokines relevant to inflammatory diseases. Excessive or persistent cytokine signalling contributes to the inflammatory environment characteristic of RA. Therefore, interfering with this pathway provides a mechanism for reducing downstream inflammatory activity. Upadacitinib is designed to preferentially inhibit JAK1. The term “JAK1 switch” in the title is therefore a useful metaphor: rather than literally switching inflammation off, the drug reduces an important intracellular signalling route that helps maintain inflammatory responses.

How Upadacitinib Works in Rheumatoid Arthritis

Upadacitinib is a selective JAK1 inhibitor administered orally. By inhibiting JAK1, it decreases signalling through cytokine pathways dependent on JAK1 activity. This can reduce the expression and activity of inflammatory mediators involved in synovitis and systemic inflammation. The therapeutic consequence is not limited to one inflammatory molecule. Instead, modification of intracellular signalling can influence several cytokine-driven processes at once. This helps explain why clinical improvements may be observed across multiple domains of RA, including tender and swollen joints, pain, morning stiffness, physical function, and overall disease activity. Importantly, JAK signalling also contributes to normal immune defence and hematopoietic processes. Consequently, therapeutic inhibition can produce adverse effects as well as anti-inflammatory benefits. This dual nature makes appropriate patient selection and monitoring particularly important.

Therapeutic Role in Rheumatoid Arthritis

Upadacitinib may be used in adults with moderately to severely active RA when conventional treatment has not provided sufficient control or has not been tolerated, according to applicable regulatory indications. Treatment decisions should be individualised according to previous DMARD exposure, disease severity, comorbidities, infection risk, cardiovascular risk, and patient preferences. Clinical guidelines emphasise a treat-to-target strategy in RA, in which therapy is adjusted according to disease activity rather than simply continued indefinitely without reassessment. European Alliance of Associations for Rheumatology (EULAR) recommendations recognise JAK inhibitors, including upadacitinib, as targeted synthetic DMARDs but emphasise careful assessment of cardiovascular, malignancy, and thromboembolic risk when considering their use.

Safety Profile, Tolerability, and Monitoring

As a potent immunomodulatory agent, the therapeutic benefits of Upadacitinib must be balanced against its potential risk profile. Selective JAK1 inhibition alters immune surveillance mechanisms, requiring structured baseline screening and ongoing clinical monitoring.

Infectious Risks

The primary adverse events associated with Upadacitinib stem from immune suppression. Upper respiratory tract infections, urinary tract infections, and bronchitis are among the most frequently observed. Notably, JAK inhibitors as a class carry an increased risk for Herpes Zoster reactivation (shingles), likely due to the suppression of type I and type II interferon signalling essential for antiviral defence. Prior vaccination against Herpes Zoster is highly recommended before initiating treatment.

Thrombotic Risk

Clinical surveillance of the JAK inhibitor class has highlighted a potential increase in the incidence of Venous Thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Risk factors such as advanced age, cardiovascular history, smoking, and baseline hypercoagulability require careful screening prior to prescribing Upadacitinib.

Laboratory Monitoring

Upadacitinib administration can cause transient or sustained alterations in biochemical and haematological parameters. Regular laboratory testing is recommended to monitor:

    • Haematology: Neutropenia, lymphopenia, and mild decreases in haemoglobin levels.
    • Lipid Profiles: Dose-dependent increases in total cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol, typically managed with standard lipid-lowering therapy without compromising cardiovascular risk benefit.
    • Hepatic Transaminases: Transient elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (ALT), particularly when co-administered with hepatotoxic drugs like Methotrexate.
    • Creatine Kinase: Mild elevations in serum creatine kinase without accompanying clinical myopathy.

Ayurveda Insight

While modern biomedicine targets molecular entities like JAK1 enzymes and cytokines, traditional systems of medicine explain chronic autoimmune inflammation through holistic physiological models. In Ayurveda, Rheumatoid Arthritis finds its closest clinical parallel in the disease entity known as Amavata.

The Concept of Amavata and Pathogenesis (Samprapti)

In Ayurvedic physiology, health is maintained by a state of equilibrium among the three doshas (Vata, Pitta, and Kapha), alongside a functional digestive and metabolic fire (Agni). Amavata develops through a dual pathological process:

Agni Mandya (Impaired Metabolic Fire)

Poor digestive capability leads to the incomplete digestion of food in the gastrointestinal tract, generating an endotoxic, sticky, systemic byproduct called Ama.

Vata Prakopa (Aggravation of Vata)

Factors such as a sedentary lifestyle, incompatible diet, physical overexertion, or emotional stress severely aggravate Vata dosha—the primary energy governing biological movement, circulation, and signal transmission.

The aggravated Vata acts as a transport vehicle, carrying the toxic, circulating Ama (toxins) throughout the body’s channels (Srotas) and lodging it within the synovial joints (Sleshma Sthana). Once Ama combines with Kapha and Pitta in the joints, it generates intense local inflammation, heat, swelling, severe stiffness, and structural deformity—a picture identical to the clinical presentation of Rheumatoid Arthritis.

Herbal Remedies as an Alternative to Upadacitinib by Planet Ayurveda

Planet Ayurveda is a wellness brand dedicated to promoting health through the traditional principles of Ayurveda and natural herbs. It offers a wide range of Ayurvedic formulations made with carefully selected herbs and natural ingredients. The brand focuses on supporting various aspects of health, including digestion, immunity, liver, joints, heart, and women’s wellness. Planet Ayurveda combines classical Ayurvedic knowledge with modern quality and manufacturing practices. Its products are designed to provide convenient herbal support for modern lifestyles. The brand promotes a holistic approach that considers nutrition, lifestyle, and overall well-being. Planet Ayurveda aims to make traditional Ayurvedic wellness accessible to people seeking natural healthcare solutions. Here we will discuss some formulations that can be used as a better alternative to Upadacitinib.

      1. Boswellia-Curcumin
      2. Aamvatantak Churna
      3. Ashwagandha Capsules
      4. Joint Aid Plus
      5. RumoGin 5 Capsules
      6. Yograj Guggul

Herbal Remedies as an Alternative to Upadacitinib

Buy Now Herbal Remedies as an Alternative to Upadacitinib

Buy Now Herbal Remedies as an Alternative to Upadacitinib

Product Description

1. Boswellia-Curcumin

Boswellia-Curcumin, containing Shallaki and Curcumin, provides Ayurvedic herbal support for inflammatory joint symptoms associated with rheumatoid arthritis. Boswellia is traditionally valued for supporting healthy inflammatory responses and comfortable joint movement, while curcumin contributes antioxidant and inflammation-modulating activity. Their combined action supports joint comfort, flexibility, and physical mobility in individuals experiencing stiffness and inflammatory discomfort. The formulation also supports protection against oxidative stress affecting musculoskeletal tissues. From an Ayurvedic perspective, these ingredients are used to support balanced Vata and Ama, concepts associated with stiffness, pain, and impaired joint function. This makes Boswellia-Curcumin a supportive component of an integrative approach to inflammatory joint health.

Dosage: 2 capsules twice daily with warm water, after meals.

2. Aamvatantak Churna

Aamvatantak Churna, containing Ashwagandha (Withania somnifera), Methi (Trigonella foenum-graecum), Suranjan (Colchicum luteum), Gorakhmundi (Sphaeranthus indicus), Haridra (Curcuma longa), and Sonth (Zingiber officinale), is formulated to support inflammatory joint and musculoskeletal symptoms associated with Amavata. Ashwagandha supports strength and tissue nourishment, while Haridra and Sonth provide antioxidant and inflammation-modulating properties. Methi contributes nutritional and metabolic support, while Suranjan and Gorakhmundi are traditionally used in Ayurvedic joint-care formulations. The combination supports comfortable movement, joint flexibility, and reduction of stiffness associated with inflammatory conditions. Its Deepana-Pachana action is traditionally used to support digestion and metabolic processing of Ama. Thus, Aamvatantak Churna provides a multi-herbal approach to maintaining joint function and musculoskeletal comfort.

Dosage: 1 teaspoonful twice daily with warm water, before meals.

3. Ashwagandha Capsules

Ashwagandha Capsules, containing Withania somnifera, provide supportive care for individuals experiencing weakness, fatigue, and reduced physical resilience alongside chronic inflammatory joint symptoms. Ashwagandha is traditionally classified as a Rasayana and Balya herb, supporting strength, endurance, and healthy muscle function. Its bioactive constituents, particularly withanolides, have demonstrated antioxidant and inflammation-modulating activity in experimental research. These properties support overall musculoskeletal resilience when chronic joint symptoms interfere with physical activity. Ashwagandha also supports stress adaptation and general well-being, which are relevant during prolonged inflammatory illness. In Ayurveda, its Vata-shamaka properties are associated with maintaining healthy movement and tissue strength.

Dosage: 2 capsules twice daily with warm water, after meals.

4. Joint Aid Plus

Joint Aid Plus, containing Nirgundi (Vitex negundo), Shallaki (Boswellia serrata), Guggul (Commiphora mukul), Sonth (Zingiber officinale), and Ashwagandha (Withania somnifera), provides comprehensive herbal support for joint stiffness, discomfort, and restricted mobility. Nirgundi and Shallaki are traditionally used in Ayurvedic joint-care practices for supporting comfortable movement and balanced inflammatory responses. Guggul contributes traditional support for healthy metabolism and joint function, while Sonth provides warming digestive and musculoskeletal support. Ashwagandha complements the formulation by supporting muscle strength and physical resilience. Together, these ingredients promote joint flexibility and comfort during routine movement. From an Ayurvedic perspective, the combination supports Vata balance and healthy functioning of the musculoskeletal tissues.

Dosage: 2 capsules twice daily with warm water, after meals.

5. RumoGin 5 Capsules

RumoGin 5 Capsules, containing Haridra (Curcuma longa), Sonth (Zingiber officinale), Shallaki (Boswellia serrata), Maricha (Piper nigrum), and Pippali (Piper longum), provides multi-herbal support for inflammatory joint discomfort and stiffness. Haridra and Shallaki contribute antioxidant and inflammation-modulating properties, while Sonth supports digestion and comfortable musculoskeletal function. Maricha and Pippali are traditionally valued for Deepana-Pachana activity and are also used to support the bioavailability and utilisation of other herbal ingredients. The combination is therefore directed toward joint comfort, mobility, and healthy inflammatory balance. In Ayurvedic terms, these herbs support management of Ama-Vata–associated stiffness and discomfort. RumoGin 5 consequently provides targeted herbal support for maintaining comfortable movement in inflammatory joint conditions.

Dosage: 1 capsule twice daily with warm water, after meals.

6. Yograj Guggul

Yograj Guggul, containing Commiphora mukul, Cyperus rotundus, Plumbago zeylanica, Emblica officinalis, Terminalia bellirica, Terminalia chebula, and several other Ayurvedic ingredients, is traditionally used for disorders involving Vata-associated musculoskeletal discomfort and stiffness. Guggul supports healthy inflammatory balance and joint function, while Plumbago and the digestive herbs contribute Deepana-Pachana activity. Haritaki, Bibhitaki, and Amalaki provide antioxidant and tissue-supportive properties. The formulation is traditionally valued for supporting flexibility and comfortable movement when stiffness affects the joints and muscles. Its broader Ayurvedic action focuses on balancing aggravated Vata and supporting the proper metabolism of Ama (toxins). Yograj Guggul therefore serves as a traditional supportive formulation for maintaining musculoskeletal function and joint comfort.

Dosage: 2 tablets twice daily with warm water, after meals.

Conclusion

Upadacitinib represents an important advancement in the treatment of rheumatoid arthritis by selectively targeting JAK1-dependent intracellular signalling. By reducing multiple cytokine-mediated inflammatory pathways, it can improve joint symptoms, physical function, patient-reported outcomes, and disease activity in patients with active RA, including those who have responded inadequately to other DMARDs. Clinical evidence demonstrates that these benefits can persist over several years. At the same time, JAK1 inhibition modifies immune pathways that are important for normal host defence, making safety screening and ongoing monitoring essential. Serious infections, herpes zoster, cardiovascular events, thrombosis, malignancy, and laboratory abnormalities must be considered during treatment. Upadacitinib should therefore be viewed not simply as an “inflammation switch,” but as a powerful targeted DMARD whose benefits depend on appropriate patient selection and responsible monitoring. From an Ayurvedic viewpoint, RA can be explored through the framework of Amavata and Vata-Ama interaction, but this traditional model should complement rather than replace evidence-based rheumatological management.

Herbal Remedies of Stiff Person Syndrome – Causes, Symptoms, Diagnosis & Treatment

Abstract

Neurological disorders that disturb normal muscle control can profoundly affect movement, independence, and everyday life. Some are caused by structural changes in the nervous system, whereas others arise from abnormalities in immune regulation that interfere with neural signaling. Stiff Person Syndrome (SPS) is a rare neurological disorder characterized predominantly by muscle rigidity and episodic painful spasms. It belongs to the broader group of stiff-person spectrum disorders and can present in several clinical forms, ranging from predominantly axial stiffness to severe disease involving the limbs, brainstem, and autonomic nervous system. In this article, we shall discuss Stiff Person Syndrome in detail, including its causes, clinical presentation, investigations, contemporary treatment options, Ayurvedic interpretation, and the role of selected herbal formulations in an integrated approach to neurological well-being.

Stiff Person Syndrome

Introduction

Stiff Person Syndrome is an uncommon disorder of the central nervous system in which normal inhibitory control over motor activity becomes impaired. The resulting increase in muscle activity produces persistent stiffness and episodes of spasms that can be extremely painful. The condition was originally described as “stiff-man syndrome,” although the current terminology recognizes that the disorder can affect people of any sex and can involve considerably more than generalized stiffness. SPS is now viewed as a spectrum of neuroimmunological disorders, with several clinical and antibody-defined variants. Symptoms most often begin during adulthood, commonly between the ages of 20 and 60. Women are affected more frequently than men. Because the disorder is rare and can resemble several other neurological conditions, diagnosis is often delayed. A 2023 study from a specialist autoimmune neurology center found that among people referred for suspected stiff-person spectrum disorder, only 28% ultimately received the diagnosis, illustrating the importance of specialist evaluation and confirmatory testing. Recent literature also indicates that stiff-person spectrum disorders are probably more common and more heterogeneous than previously appreciated.

What Happens in Stiff Person Syndrome?

Normal movement depends on a carefully regulated balance between excitatory and inhibitory signals within the nervous system. One of the most important inhibitory neurotransmitters is gamma-aminobutyric acid (GABA). GABA acts as a neurological “brake,” preventing excessive activation of motor pathways. In many individuals with SPS, antibodies directed against glutamic acid decarboxylase 65 (GAD65) are detectable. GAD65 is involved in the synthesis of GABA. Other patients have antibodies against proteins such as the glycine receptor or amphiphysin. These immune markers help characterize different forms of the disease, although antibody results must always be interpreted in combination with the clinical and electrophysiological findings. The result is excessive motor excitability and inadequate inhibition of muscle activity.

Stiff-Person Spectrum Disorders

SPS does not have a single presentation. The spectrum includes several phenotypes.

Classic Stiff Person Syndrome

This is the most recognized form. It usually involves progressive stiffness of the:

  • Trunk
  • Lower back
  • Abdomen
  • Hips
  • Legs

Painful spasms can occur when the patient encounters an unexpected stimulus.

Stiff-Limb Syndrome

Stiffness and spasms are predominantly confined to one or more limbs.

SPS Plus

Patients can have classic SPS manifestations together with additional neurological abnormalities.

Progressive Encephalomyelitis With Rigidity and Myoclonus

This is a more extensive form involving the brainstem and spinal cord. It can be associated with:

  • Severe rigidity
  • Myoclonus
  • Abnormal eye movements
  • Swallowing dysfunction
  • Autonomic disturbance
  • Respiratory complications

Causes and Associated Conditions

The exact event that initiates the abnormal autoimmune response remains unclear. SPS is nevertheless strongly associated with autoimmune disease.

Anti-GAD65 Autoimmunity

GAD65 antibodies are frequently identified in classic SPS. High antibody concentrations strengthen the diagnostic picture when they occur with compatible clinical and electrophysiological findings.

Other Autoantibodies

Some patients have:

  1. Glycine-receptor antibodies
  2. Amphiphysin antibodies
  3. Other neural autoantibodies

These antibody profiles can be associated with distinct clinical presentations.

Associated Autoimmune Diseases

SPS can occur in association with:

  • Type 1 diabetes mellitus
  • Autoimmune thyroid disease
  • Pernicious anemia
  • Vitiligo
  • Other autoimmune disorders

The National Institute of Neurological Disorders and Stroke notes that autoimmune conditions are common among individuals with SPS.

Paraneoplastic Disease

A smaller subgroup develops SPS-spectrum symptoms in association with malignancy. Amphiphysin antibodies have a particularly important association with paraneoplastic forms, making cancer evaluation relevant in appropriately selected patients.

Risk Factors

There is no single lifestyle factor that causes SPS.
Factors associated with the condition include:

  • Personal autoimmune disease
  • Family tendency toward autoimmunity
  • Female sex
  • Adult age
  • Certain malignancies in paraneoplastic cases

The disorder should not be confused with ordinary muscular stiffness caused by sedentary behavior, exercise, aging, or posture.

Signs and Symptoms

The presentation develops gradually in many patients.

Persistent Muscle Stiffness : Rigidity often affects the axial muscles first, especially the abdomen and lower back. The muscles may feel continuously contracted rather than simply tight after physical activity.

Painful Spasms : Spasms are a defining feature and can occur suddenly.
Triggers include:

  • Unexpected noise
  • Sudden touch
  • Emotional distress
  • Sudden movement
  • Fear
  • Attempting to move rapidly

The intensity can be considerable and can sometimes cause falls or physical injury.

Abnormal Posture : Persistent contraction of the trunk muscles can produce excessive lumbar curvature and a stiff posture.

Walking Difficulty : As stiffness progresses, patients may develop:

  • Slow gait
  • Difficulty turning
  • Difficulty climbing stairs
  • Unsteadiness
  • Fear of falling
  • Frequent falls

Pain : Chronic muscular contraction can result in widespread musculoskeletal pain.

Exaggerated Startle Response : An unusually strong response to unexpected sensory stimuli is a distinctive clinical clue.

Anxiety : Anxiety frequently accompanies SPS. There can be a reciprocal relationship in which anxiety increases the likelihood of spasms, while fear of a future spasm increases anxiety.

Autonomic and Other Neurological Symptoms : Severe stiff-person spectrum disease can extend beyond muscle stiffness.
Possible manifestations include:

  • Excessive sweating
  • Fluctuations in blood pressure
  • Rapid heartbeat
  • Temperature dysregulation
  • Difficulty swallowing
  • Speech difficulties
  • Abnormal eye movements
  • Respiratory dysfunction

These features are particularly important in severe SPS-spectrum presentations.

How Stiff Person Syndrome Affects Daily Life

The consequences extend beyond the neurological examination. A patient may gradually reduce:

  • Walking
  • Travelling
  • Social activities
  • Employment
  • Exercise
  • Independent living

Some individuals become afraid of crowded or unpredictable environments because unexpected sounds or touch can provoke spasms.

This creates a cycle:

Trigger → spasm → fear → avoidance → reduced confidence → greater functional limitation
Breaking this cycle requires both neurological treatment and rehabilitation.

Investigations

Because no single test establishes every SPS diagnosis, evaluation combines clinical, laboratory, and electrophysiological information.

Neurological Examination : The physician assesses:

  • Muscle tone
  • Distribution of rigidity
  • Deep tendon reflexes
  • Startle response
  • Gait
  • Balance
  • Coordination
  • Strength
  • Associated neurological findings

Autoantibody Testing : Testing can include:

  • GAD65 antibodies
  • Glycine receptor antibodies
  • Amphiphysin antibodies
  • Other neural antibody panels when indicated

High-titer GAD65 antibodies are more meaningful when combined with a characteristic clinical picture. Low levels can occur in other settings, including diabetes, and should not be interpreted in isolation.

Electromyography : Electromyography can demonstrate continuous involuntary motor-unit activity, a particularly useful finding in SPS. It also assists in distinguishing SPS from other causes of rigidity.

MRI : MRI of the brain and spinal cord is commonly used to rule out:

  • Structural spinal disease
  • Multiple sclerosis
  • Brain lesions
  • Myelopathy
  • Other causes of rigidity

Cerebrospinal Fluid Analysis : Lumbar puncture can be considered when an inflammatory or encephalomyelitic form is suspected.

Cancer Screening : Patients with atypical features or antibodies associated with paraneoplastic disease may require appropriate malignancy screening.

Differential Diagnosis : A number of conditions can resemble SPS.
These include:

  • Parkinsonian rigidity
  • Multiple sclerosis
  • Dystonia
  • Spasticity from spinal cord disorders
  • Neuromyotonia
  • Tetanus
  • Functional neurological disorder
  • Drug-induced rigidity
  • Myelopathy
  • Other autoimmune neurological disorders

A specialist evaluation is therefore particularly valuable. The 2023 Mayo Clinic series demonstrated that misdiagnosis was substantially more frequent than confirmed SPS among referred suspected cases.

Contemporary Management : There are two principal treatment objectives: Control abnormal muscle activity and address the immune-mediated component of the disease

.Symptomatic Treatment : Treatment plans are individualized because responses differ substantially across the stiff-person spectrum. A 2025 systematic review identified considerable variation in treatment responses and emphasized the need for individualized strategies.

Benzodiazepines : Diazepam and other benzodiazepines enhance GABA-mediated inhibitory signaling and can significantly reduce stiffness and spasms. They remain an important part of symptomatic treatment.

Baclofen : Baclofen acts on GABA-B receptors and can reduce muscle overactivity.

Gabapentin and Pregabalin : These agents can be considered when pain and spasms remain troublesome.

Tizanidine : Tizanidine can provide additional muscle-relaxant effects in selected patients.

Other Agents : Dantrolene and other symptom-directed treatments can be considered according to the patient’s clinical status.

Immunotherapy : Symptom control does not address the underlying immune abnormality. Patients with significant autoimmune SPS can therefore require immunomodulatory treatment.

Intravenous Immunoglobulin : IVIG is one of the most important immunotherapies used in SPS. It can reduce stiffness and improve functional ability in appropriately selected patients.

Corticosteroids : Steroids can be used to suppress abnormal immune activity in selected circumstances.

Plasma Exchange : Plasma exchange is considered in particular severe or refractory cases.

Rituximab : Rituximab has been used in difficult-to-treat disease because of its B-cell-directed action. Evidence remains heterogeneous, and patient selection is important.

Treatment of Paraneoplastic Disease : When SPS occurs as part of a paraneoplastic syndrome, identifying and treating the underlying malignancy becomes a major component of management

Physiotherapy and Rehabilitation : Rehabilitation helps preserve independence even when neurological symptoms are chronic. A customized program can include:

  • Gentle stretching
  • Range-of-motion exercises
  • Balance training
  • Gait training
  • Strength maintenance
  • Occupational therapy
  • Fall prevention

The pace should be individualized because sudden movement and excessive stimulation can provoke spasms.

Psychological Management : Psychological care deserves particular attention. People with SPS can become apprehensive about:

  • Falling
  • Sudden sounds
  • Physical contact
  • Leaving home
  • Entering crowded spaces
  • Experiencing another severe spasm

Counseling, relaxation techniques, controlled breathing, mindfulness, and treatment of clinically significant anxiety can improve coping and participation in rehabilitation.

Ayurvedic View and Management of Stiff Person Syndrome

Stiff Person Syndrome does not have a direct one-to-one equivalent in the classical Ayurvedic disease nomenclature. Considering its principal features—persistent stiffness, painful involuntary contractions, altered movement, and neuromuscular dysfunction—the most appropriate single Ayurvedic correlation is a Vata-dominant Snayu-Mamsa disorder within the broader spectrum of Vata Vyadhi. Vata governs movement, nerve-related functions, muscle activity, and coordination. Excessive exertion, irregular sleep, inadequate nourishment, chronic stress, excessive fasting, and tissue depletion can aggravate Vata. Once aggravated, Vata localizes in Snayu (ligaments), Mamsa (muscle), Asthi (bones), and Majja (soft tissue), disturbing the normal alternation between muscular contraction and relaxation. This produces:

  • Stambha – stiffness
  • Akshepa – involuntary contractions or spasms
  • Shoola – pain
  • Cheshta Vaishamya – disturbed movement
  • Functional restriction

The Ayurvedic sequence can therefore be represented as:

Vata Prakopa → Snayu-Mamsa-Majja involvement → disturbance of neuromuscular movement → Stambha and Akshepa → rigidity, painful spasms and impaired mobility.

This provides a focused Ayurvedic framework for interpreting the major motor manifestations of SPS without claiming that SPS itself is explicitly described in classical texts.

The Ayurvedic approach is centered on Vata Shamana, Snehana, Swedana, Brimhana, Rasayana, and rehabilitation. Warm oil massage can help address Vata-related stiffness and muscular tension. Appropriate Swedana introduces controlled warmth to promote flexibility. In a properly selected patient, Basti can form an important part of a Vata-management program. Nourishing food, adequate sleep, gentle physical activity, meditation, Pranayama, and a regular daily routine further reinforce Vata stability. The nutritional approach should emphasize freshly prepared, warm, nourishing foods containing adequate protein, healthy fats, whole grains, vegetables, and appropriate sources of micronutrients. Excessive fasting, irregular meals, sleep deprivation, and abrupt strenuous exercise should be avoided. Ayurvedic management should be individualized according to Prakriti, Bala, Agni, age, disease severity, medication use, and neurological status.

Ayurvedic Lifestyle Plan for Neuromuscular Stiffness

Herbal management becomes more meaningful when accompanied by consistent lifestyle practices.

Warmth and Oil Application : Vata-associated stiffness benefits from an appropriately warm environment and physician-directed oil therapies.

Gentle Movement : Prolonged immobility can worsen functional decline. Safe, gradual movement should be incorporated according to the patient’s neurological status.

Sleep : Consistent restorative sleep is important for physical recovery and emotional regulation.

Breathing and Meditation : Slow breathing and meditation can reduce psychological arousal and help patients respond more calmly to triggers.

Nourishing Diet : A balanced diet with adequate protein, healthy fats, whole grains, vegetables, and micronutrients helps maintain physical strength.

Herbal Remedies for Stiff Person Syndrome by Planet Ayurveda

Planet Ayurveda is a dedicated Ayurvedic healthcare organization that offers a wide range of herbal formulations designed to support overall health and wellness. The company draws inspiration from the fundamental principles of Ayurveda and combines them with modern quality practices to develop convenient herbal products. Its portfolio includes capsules, tablets, powders, syrups, oils, and specialized herbal combinations prepared from carefully selected ingredients. With a focus on purity and authenticity, Planet Ayurveda aims to promote a balanced approach to wellness and help individuals incorporate the benefits of Ayurveda into their daily lives. Planet Ayurveda provides Ayurvedic herbal formulations prepared from selected herbs and classical combinations for neurological, musculoskeletal, digestive, and general wellness applications.  Planet Ayurveda is pleased to present its Stiff-Man Care Pack for an Ayurvedic approach to stiffness, muscular discomfort, restricted mobility, and associated neurological well-being.

Product List

  1. Boswellia-Curcumin
  2. Hakam Churna
  3. Brahmi Capsules
  4. Ashwagandha Capsules
  5. Kaishore Guggul

Herbal Remedies of Stiff Person Syndrome

Buy Now Herbal Remedies of Stiff Person Syndrome

Buy Now Herbal Remedies of Stiff Person Syndrome

Produts Discription

1. Boswellia-Curcumin

Planet Ayurveda’s Boswellia-Curcumin combines Shallaki (Boswellia serrata) and Curcumin (Curcuma longa), with 250 mg of each per capsule. Shallaki provides boswellic acids, while Curcumin supplies curcuminoids with antioxidant and inflammation-modulating activity. The combination is positioned for joint and muscle health, pain management, and comfortable mobility.

Dosage: 2 capsules twice daily.

2. Hakam Churna

Planet Ayurveda’s Hakam Churna contains Chandershoor (Lepidium sativum), Kalonji (Nigella sativa), Methi (Trigonella foenum-graecum), and Ajwain (Trachyspermum ammi). These herbs provide a digestive and metabolic component to the regimen. In Ayurveda, maintaining healthy Agni (digestion) is particularly important when managing Vata-related conditions because impaired digestion. With its Vata alleviation properties, it helps in the management of stiffness and pain associated with Stiff person syndrome.

Dosage: 1 teaspoon twice daily.

3. Brahmi Capsules

Planet Ayurveda’s Brahmi Capsules contain standardized Brahmi (Bacopa monnieri) root extract, 500 mg per capsule. Brahmi is an important Medhya herb associated with cognitive and neurological well-being. Its bacosides are the principal bioactive constituents associated with its neurological activity. Within an Ayurvedic regimen for neurological health, Brahmi contributes a Medhya and mind-supporting dimension that complements physical management of stiffness and functional limitations and also helps in managing psychological stress.

Dosage: 2 capsules twice daily.

4. Ashwagandha Capsules

Planet Ayurveda’s Ashwagandha Capsules contain standardized Ashwagandha (Withania somnifera) root extract, 500 mg per capsule. Ashwagandha contains bioactive withanolides and  it has Medhya (cognition enhancing), Rasayana (rejuvenation), and Dhatu Pushti  (tissue replenishing) properties, with particular emphasis on Vata and Kapha balance and neurological well-being. Its place in this regimen is centered on maintaining neurological health, physical strength, resilience, and healthy stress adaptation.

Dosage: 1 capsule twice daily.

5. Kaishore Guggul

Kaishore Guggul is a classical polyherbal formulation containing Amalaki (Emblica officinalis), Bibhitaki (Terminalia bellirica), Haritaki (Terminalia chebula), Guggul (Commiphora mukul), Guduchi (Tinospora cordifolia), Ginger (Zingiber officiale), Black Pepper (Piper nigrum), Long Pepper (Piper longum), Vidanga (Embelia ribes), and other ingredients. Its combination of Guggul, Guduchi, Triphala, and Trikatu provides a formulation oriented toward metabolic balance, digestion, and inflammatory wellness. It helps in reducing stiffness and ease body movements.

Dosage: 2 tablets twice daily.

Conclusion

Stiff Person Syndrome is a rare and complex neurological disorder in which abnormal motor excitability produces persistent rigidity, painful spasms, exaggerated startle responses, and progressive difficulty with movement. Its clinical spectrum is broad, extending from classic axial stiffness to stiff-limb presentations and severe forms involving brainstem, spinal cord, myoclonus, and autonomic dysfunction. The diagnostic process requires careful clinical assessment together with appropriate antibody testing and electromyography, while MRI and other investigations help exclude alternative neurological diseases. Contemporary treatment works through two complementary pathways. Symptomatic medicines such as benzodiazepines, baclofen, gabapentin, pregabalin, and other muscle-relaxing agents help control stiffness and spasms, while immunotherapies such as IVIG, corticosteroids, plasma exchange, and selected B-cell-directed therapies address the immune component in appropriately selected patients. Rehabilitation and psychological care are essential for maintaining mobility, reducing falls, and preserving independence.

From an Ayurvedic perspective, the predominant manifestations of SPS can be understood through a Vata-dominant Snayu-Mamsa-Majja pathology, characterized by Stambha, Shoola, and Akṣepa. The Ayurvedic approach consequently emphasizes Vata Shamana, Snehana, Swedana, Brimhana, Rasayana, nourishment, regular sleep, gentle movement, and individualized Panchakarma. Planet Ayurveda’s Stiff-Man Care Pack provides a focused Ayurvedic regimen addressing musculoskeletal comfort, neurological wellness, metabolic balance, and overall vitality. A well-rounded management strategy therefore brings together accurate diagnosis, specialist neurological treatment, immunotherapy where indicated, symptom control, rehabilitation, psychological care, and individualized Ayurvedic management. The objective is to preserve movement and independence while helping the individual build a sustainable routine around a challenging neurological condition.